Abstract. It has been reported that Salvador (SAV) is a core component of the Salvador-Warts-Hippo (SWH) pathway that restricts cell number, by functioning as a dual regulator of cell proliferation and apoptosis in Drosophila. However, the function of its human ortholog hSav1 (also called hWW45) in mammalian cells is poorly understood. In this study, we identified hematopoietic cell-specific protein 1 (HS1)-associated protein X-1 (HAX1), a 35-kda protein localized to cell mitochondria, as a novel binding partner of hSav1 using a yeast two-hybrid screening technique. Our finding was confirmed by immunoprecipitation and glutathione-S-transferase (GST) pull-down assays of both proteins. Using immunofluorescence staining, we showed that HAX1 and hSav1 interact with each other. Analysis of the anti-apoptotic function of HAX1 revealed that the presence of hSav1 attenuated the HAX1 protective effects from hydrogen peroxide (H 2 O 2 )-induced cell death in McF-7 cells, while knockdown of hSav1 by small interfering RNAs (siRNAs) significantly enhanced the anti-apoptotic function of HAX1. Also, using the Oncomine database, we found several studies in which HAX1 levels were significantly up-regulated and hSav1 expression was down-regulated in breast cancer samples compared to normal breast tissue. In summary, we conclude that hSav1 interacts with HAX1 and attenuates its protective role against apoptosis in McF-7 breast cancer cells.
Introduction
Apoptosis is a form of cell death with critical functions both in the development of organisms and in maintaining cellular homeostasis throughout life. Many signaling pathways control these important cellular processes, including the recently described Salvador-Warts-Hippo (SWH) pathway, which includes several tumor suppressor genes, such as: fat (1,2) merlin (3), expanded, hippo (4) , RASSF (5) , Lats/Warts (6) , Salvador (7) and an oncogene called yorkie (8) (9) (10) and controls cell growth, proliferation, and apoptosis (10) . The ortholog of hSav1 in Drosophila, Salvador (SAV), has been reported as a core component of the SWH pathway.
SAV is a scaffold protein containing a WW domain that interacts with Warts (WTS) and a c-terminal SAV-RASSF-HPO (SARAH) domain that mediates binding to Hippo (HPO) (11) . The primary function of SAV is likely to facilitate the close association of WTS and HPO kinases, and/or to recruit HPO to its site of activation (12) (13) (14) . SAV promotes both cell cycle exit and apoptosis through the modulation of both cyclin E and dIAP (Drosophila inhibitor of apoptosis protein) in Drosophila. However, the cellular function of hSav1 in mammalian cells is poorly understood. To better understand the mechanistic function of hSav1, it is necessary to identify new substrates for this protein. In the present study, we investigated the interaction between the hematopoietic cell-specific protein 1 (HS1)-associated protein X-1 (HAX1) and hSav1, which has been examined in previous studies (15) .
HAX1 is a 35-kda anti-apoptotic protein that has sequence similarity to the Nip3 protein and shares homology with the BH1 and BH2 domains from the Bcl-2 family of proteins (15) . HAX1 was originally identified in a yeast two-hybrid assay on the basis of its binding to HS1. The HAX1 protein appears to be expressed ubiquitously in various tissues and is localized mainly in mitochondria, but is also found in the endoplasmic reticula and nuclear envelopes of cells. HAX1 is involved in both death receptor and mitochondria-mediated apoptosis pathways. Previous studies showed that HAX1 is a potent inhibitor of Bcl-2-associated X protein (Bax)-induced apoptosis (16) . Furthermore, it has been demonstrated that HAX1 is degraded in the mitochondria by the high temperature requirement protein A2 (Omi/HtrA2) after induction of apoptosis, which contributes to caspase-independent induction of apoptosis by Omi/HtrA2 (17) . An additional study showed both that HAX1 is overexpressed in psoriatic skin using in situ hybridization and that keratinocytes isolated from psoriatic plaques, which are characterized by hyperproliferation and resistance to apoptosis, also overexpressed HAX1 (18) . Recently, it was reported that HAX1 is an anti-apoptotic molecule that protects cardiac myocytes from hypoxia/reoxygenation-induced apoptosis by inhibiting caspase-9 (19, 20) . Furthermore, the authors showed that HAX1 deficiency causes Kostmann disease, a severe, autosomal, recessive type of congenital neutropenia. Although many studies have touched upon the various roles of HAX1, certain questions remain unanswered. In this study, we aimed to demonstrate that HAX1 is a novel binding partner of hSav1.
Materials and methods
Reagents. The reagents we used in this study are as follows: dulbecco's modified Eagle's medium (dMEM) and fetal bovine serum (FBS) were purchased from Gibco (carlsbad, CA, USA). Monoclonal antibodies specific for hemagglutinin (HA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Anti-hSav1 monoclonal antibody was purchased from Abnova (Taipei city, Taiwan, china). cleaved poly-(AdPribose) (PARP) and cleaved caspase-9 were purchased from cell Signaling Technology (danvers, MA, USA). Horseradish peroxidase-conjugated secondary antibodies (anti-rabbit or anti-mouse IgG) and FITc-and TRITc-conjugated goat antibodies to mouse or rabbit IgG were purchased from Pierce (Rockford, IL, USA). Anti-HAX1 monoclonal antibody and an Annexin V and propidium iodide (Annexin V/PI) kit was purchased from Bd Biosciences (San diego, cA, USA). Protein A Sepharose™ cL-4B was purchased from Amersham Biosciences AB (Uppsala, Sweden). Other chemical reagents were purchased from Generay Biotech (Wuhan, china) or Tiangen co. (Wuhan, china), unless otherwise noted.
Plasmid construction. Full-length HAX1 was isolated from a human, fetal liver, cdNA library and cdNA was subcloned into pcMV-FLAG4, pEGFP-N1 and pGEX-4T1 plasmids. HAX1 mutants were also generated by polymerase chain reaction (PcR) and cloned into the pGEX-4T1 plasmid. Similarly, cdNA for hSav1 was obtained from a human, fetal liver, cdNA library, but was subcloned into pcMV-HA, pEGFP-N1 and pGEX-4T1 plasmids. Sequence verified constructs were used in all experiments.
Cell culture and transfection. HEK293 and McF-7 cells were cultured in dMEM supplemented with 10% FBS, 100 U/ml penicillin and 0.1 mg/ml streptomycin in a 5% cO 2 atmosphere at 37˚C. Transfections were performed using the Lipofectamine 2000 reagent, according to the manufacturer's instructions (Invitrogen, carlsbad, cA, USA).
Small interfering RNA (siRNA) experiments. In order to down-regulate hSav1 using siRNAs, we purchased the following sequences from RiboBio co. (Guangzhou, china): si-hSav1-sense, (5'-3')-ccAUGAUcUcUUccAAAGAdTdT; antisense, (3'-5')-dTdTGGUAcUAGAGAAGGUUUcU; scrambled siRNA was used as a control. cells were seeded in 6-well plates and transfected with siRNA duplexes using Lipofectamine 2000 (Invitrogen), according to the manufacturer's recommendations.
Yeast two-hybrid screen. Yeast two-hybrid screening was performed using the Matchmaker Two-Hybrid System 3, according to the manufacturer's protocol (clontech, Palo Alto, CA, USA). Briefly, the open reading frame of wild-type human hSav1 was fused to the dNA-binding domain of the yeast transcription factor GAL4 and used as bait after transformation into the Saccharomyces cerevisiae strain AH109. To screen for proteins that interact with hSav1, the human fetal liver library was fused to the transcription-activating domain of GAL4 (Clontech). Positive clones were amplified and plasmids were rescued and sequenced to identify the interacting partner.
Western blot analysis and immunoprecipitation. cell lysates were extracted into a cold lysis buffer [Tris-Hcl pH 7.5, 150 mM Nacl, 1 mM EdTA, 1 mM Mgcl 2 , 0.5% Triton X-100, phosphatase inhibitor mixture (1 mM NaF, 1 mM Na 3 VO 4 and 1 mM β-glycerophosphate), and a protease inhibitor mixture (1 mmol/l PMSF, 2 µg/ml aprotinin, 1 µg/ml leupeptin and 1 µg/ml pepstatin A)]. Lysates were clarified by centrifugation at 10,000 x g for 20 min. For immunoprecipitation, the lysates were incubated with 1 µg of primary antibodies for 2 h at 4˚C with rocking, followed by protein A sepharose beads for 4 h at 4˚C. The bound immunocomplexes were washed six times with cold lysis buffer, and eluted into 60 µl 1X SdS, by boiling the samples for 5 min. The supernatant was collected after centrifugation at 4000 x g for 5 sec. The samples were resolved on an SdS-PAGE gel and transferred to a PVdF membrane (Amersham Biosciences). The membrane was blocked in TBS-T buffer (20 mM Tris-Hcl, pH 7.5, 150 mM Nacl and 0.05% Tween-20) containing 5% (w/v) non-fat milk at room temperature for 1 h and then incubated with the primary antibody overnight at 4˚C, followed by incubation with horseradish peroxidase-conjugated anti-IgG for 1 h at room temperature. Bands were visualized using a SuperSignal West Femto Maximum Sensitivity Substrate Trial kit (Pierce).
Generation and purification of glutathione-S-transferase (GST)
proteins, GST pull-down assay. GST proteins were induced with 0.1 mM isopropyl-β-d-thiogalactopyranoside (IPTG) for 3 h after transforming the plasmids into Escherichia coli dH10B (Invitrogen). Proteins were purified after affinity chromatography on glutathione Sepharose™ 4B (Amersham Biosciences). HEK293 cells were transiently transfected with the indicated expression plasmids and harvested 36 h after transfection. GST pull-down was performed by incubating 1 mg of whole-cell extracts with equal amounts of recombinant GST and GST-HAX1 or HAX1 mutants at 4˚C overnight. The beads were washed three times with 10 mM NaPO 4 (pH 7.2), 10 mM NaN 3 , 120 mM Nacl, 0.1% (v/v) Tween-20 mixture at 4˚C and were suspended in 2X SDS sample buffer. Samples were analyzed by Western blot analysis.
Immunofluorescence. cells grown on chamber slides were transfected with indicated plasmids and fixed with 4% formaldehyde in phosphate-buffered saline (PBS) for 10 min. When MitoTracker was used, it was added to the cell culture for 30 min before fixation. Cells were permeabilized in PBS containing 0.1% Triton X-100 for 10 min, and blocked with 2% bovine serum albumin prepared in PBS for 10 min. cells were then incubated with anti-hSav1 or anti-HAX1 monoclonal antibodies (1 µg/ml) for 1 h. FITc-or TRITc-conjugated goat antibodies to mouse IgG were used at a dilution of 1:100 for 45 min. cells were washed with PBS and nuclei were stained with PI (10 µg/ml) for 15 min. Images were captured using a Leica confocal laser scanning microscope (Leica Laser Technik GmbH, Heidelberg, Germany).
Assessment of cell death. After transfecting cells with the indicated plasmids (24-48 h), cells were mixed with the pro-apoptotic agent H 2 O 2 (2 mM) for 15 h. Apoptotic cells were quantified using Sub-G1-and Annexin V/PI-based flow cytometry, as described previously (21, 22) .
Databases. We used the Oncomine cancer microarray database (23) (http://www.oncomine.org) to study the gene expression of HAX1 and hSav1 in human breast tumor types and their normal tissue counterparts (24) (25) (26) (27) (28) (29) . In order to compare the gene expression in a tumor type to its normal counterpart, gene expression data from a same study, performed with the same methodology, were used. The gene expression data were log transformed, median centered per array, and the standard deviation was normalized to one per array. A gene was considered as overexpressed when its mean value in tumor samples was significantly higher to its mean value in the normal tissue counterpart using a Student's t-test (P<0.05).
Statistical analysis. All data were expressed as the mean ± SEM (standard error of the mean). Between-group and amonggroup comparisons were conducted using Student's t-tests and ANOVA, respectively. Differences were considered significant when P<0.05.
Results

Interaction between hSav1 and HAX1 in vivo.
To identify proteins that interact with hSav1, we used a yeast two-hybrid system. Of a total of 1.23x10 6 clones screened under highstringency conditions, 30 positive clones were identified. Three of these clones contained the full-length or a part of the cdNA sequence of HAX1. To confirm this interaction, co-immunoprecipitation experiments were carried out in HEK293 cells. HEK293 cells were transfected with a construct encoding the full-length hSav1 fused to a hemagglutinin (HA) tag. Anti-HA tag antibody was used to precipitate HA-tagged hSav1. Western blot analysis with HAX1 antibodies was used to monitor the presence of HAX1 protein in the precipitated complex. HA-tagged hSav1 co-precipitated with HAX1 from lysates of transiently transfected HEK293 cells, while it failed to co-precipitate from the control plasmid. Similarly, HAX1 endogenous to HEK293 cells co-precipitated with recombinant HA-tagged hSav1, but not with the control plasmid ( Fig. 1A and B) .
Further evidence that HAX1 and hSav1 interact in vivo was provided by immunofluorescence studies. HAX1, originally McF-7 cells were transfected with hSav1-GFP, as previously described. After 36 h, cells were fixed and immunostained with anti-HAX1 antibody followed by TRITC-conjugated anti-mouse IgG (red). Cells were visualized using confocal laser scanning microscopy. co-localization of hSav1 and HAX1 yields a yellow color after merging the images. isolated as an HS1 binding protein, is known to localize mainly in cellular mitochondria. In this study, we confirmed that HAX1 is mainly localized in the mitochondria of cells (Fig. 1c) . We also examined whether HAX1 co-localizes with hSav1 in mammalian cells. Our results show that, in microscopy-derived images of cells, hSav1 (green) and HAX1 (red) co-localized, yielding a yellow color (Fig. 1d) . Thus, we conclude that a substantial portion of HAX1 co-localizes with hSav1 in McF-7 cells.
Association of hSav1 and HAX1 in vitro.
To verify if hSav1 and HAX1 directly interact with each other in vitro, we carried out GST pull-down assays. It is established that HAX1 contains BH1 (37-56), BH2 (74-89), PEST (104-117) and transmembrane domains (261-273). To investigate the importance of various related HAX1 domains in binding to hSav1, we generated deletion mutants lacking the various domains (Fig. 2A) . The domains were expressed as GST-fusion proteins in E. coli and purified using glutathione sepharose. Equivalent amounts of either GST-HAX1 deletion mutants or control GST proteins bound to glutathione matrices were incubated with lysates of HEK293 cells, which were transiently transfected with a vector encoding a HA-tagged version of hSav1. The bound proteins were eluted and subjected to Western blot analysis (Fig. 2B and c) . Results from these experiments showed that the HAX1 derived peptide corresponding to amino acids 208-279 of the fusion protein was sufficient for binding to hSav1. The GST protein alone did not bind to hSav1.
hSav1 attenuates the anti-apoptotic function of HAX1.
Previous reports have demonstrated an anti-apoptotic function for HAX1. In order to determine whether the presence of hSav1 may influence its anti-apoptotic role, we performed transient transfections of Flag-HAX1, HA-hSav1 or co-transfections of both constructs in McF-7 cells. cell death was induced by exposure to 2 mM H 2 O 2 for 15 h. At the end of the incubation period, cell death was determined by the Sub-G1 and Annexin V/PI flow cytometry assays. Cells co-transfected with the empty vectors were used as controls. Treatment with H 2 O 2 induced 30% cell death in the control cells, whereas the HAX1 transfected cells displayed decreased cell death (~15%), compared to the control cells (Fig. 3A) . However, the anti-apoptotic effect of HAX1 was attenuated when it was co-transfected with hSav1 (~30% cell death) (n=3, P<0.05). Also, a same pattern was observed when we used the Annexin V/PI assay (Fig. 3B) . HAX1 transfected cells showed a decreased cell death compared to control cells (~32 vs. ~57%; n=3, P<0.05) and the anti-apoptotic effect of HAX1 was attenuated when it was co-transfected with hSav1 (~32 vs. ~53%; n=3, P<0.05). Next, we evaluated the anti-apoptotic function of HAX1 after knockdown of endogenous hSav1 in MCF-7 cells. Significantly, knockdown the endogenous hSav1 enhanced the anti-apoptotic function of HAX1, either in the Sub-G1 assay (Fig. 3d ) (~21 vs. ~10%; n=3, P<0.05) or in the Annexin V/PI assay (Fig. 3E ) (~29 vs. ~16%; n=3, P<0.05). These findings were further confirmed by the subsequent protein changes shown in Fig. 3c and F. HAX1 and hSav1 expression in breast cancer. In the present study, we queried the Oncomine database to systematically assess relative gene expression levels of HAX1 and hSav1 in breast cancer. We found that HAX1 expression was significantly higher in breast cancer compared with normal breast tissue in seven microarray expression studies (Fig. 4A) . Similar analysis of hSav1 showed that it was also significantly down-regulated in five microarray expression studies (Fig. 4B) .
Discussion
In the present study, we identified HAX1 as a novel binding partner for hSav1. We also showed that HAX1 is critical for protecting against apoptosis and that hSav1 attenuated the anti-apoptotic effects of HAX1 in H 2 O 2 -induced apoptosis in McF-7 cells. Finally, we used the Oncomine database to show that HAX1 expression was up-regulated while hSav1 was down-regulated in breast cancer samples.
Studies in Drosophila have uncovered a growth regulatory pathway mediated by HPO, the Drosophila ortholog for the MST (mammalian sterile 20-like kinase) family, which promotes apoptosis and restricts cell proliferation in conjunction with the scaffold protein SAV (6, 7, 12) as part of the SWH pathway. It was previously shown that SAV regulates apoptosis by virtue of its ability to modulate the levels of dIAP1; loss of the gene Sav increased dIAP1 levels; the human ortholog of Drosophila Sav, hSav1, codes for an ubiquitously expressed protein consisting of two WW domains and a coiled-coil region with a molecular mass of ~45 kda (30) .
We showed that HAX1, a 35-kda mitochondrial outer membrane protein, binds to hSav1. HAX1 is known to participate in both death receptor and mitochondria-mediated apoptosis pathways (16) and functions as an endogenous anti-apoptotic molecule. We found that the c-terminal 80-amino acid sequence (208-279) of HAX1, consisting of a transmembrane domain, is required for binding to hSav1.
Other studies have suggested that HAX1 is involved in both stabilization of the mitochondrial membrane potential and in protection against apoptosis (31, 32) . Permeabilization of mitochondrial membranes is often a rate-limiting process in apoptotic cell death (33, 34) . It has been reported that HAX1 regulates carcinoma cell migration and invasion via clathrinmediated endocytosis of integrin αvβ6 and progression of oral cancer has been associated with enhanced expression of αvβ6 and HAX1 proteins in patient tissue (35) . In the present study, the HAX1 protected against cell death in McF-7 breast cancer cells. We also found that HAX1 is up-regulated in breast cancer samples compared to normal breast tissues by searching the Oncomine database, and therefore it may also play an important role in breast cancer progression. Recently the Hippo signaling pathway was reported to be a critical regulator of mammalian liver growth and a potent suppressor of liver tumor formation (36) . The mammalian Hippo-Salvador pathway restricts the proliferation of hepatic oval cells and thereby controls liver size and prevents the development of oval cell-derived tumors (37) . Both of these studies suggest that hSav1 may be a potent tumor repressor of liver tumor formation. We also showed that hSav1 expression was down-regulated in breast cancer and it attenuated the anti-apoptotic function of HAX1 in McF-7 cells. Taken together, the deregulation of both hSav1 and HAX1 may play a role during breast tumorigenesis.
